441 related articles for article (PubMed ID: 23697475)
1. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
2. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Lage MJ; Fabunmi R; Boye KS; Misurski DA
Adv Ther; 2009 Feb; 26(2):217-29. PubMed ID: 19219409
[TBL] [Abstract][Full Text] [Related]
3. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
5. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
6. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
7. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
8. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
[TBL] [Abstract][Full Text] [Related]
9. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
10. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
11. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
DeKoven M; Lee WC; Bouchard J; Massoudi M; Langer J
Adv Ther; 2014 Feb; 31(2):202-16. PubMed ID: 24477354
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
Martin C; Odell K; Cappelleri JC; Bancroft T; Halpern R; Sadosky A
J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
[TBL] [Abstract][Full Text] [Related]
14. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
[TBL] [Abstract][Full Text] [Related]
15. Dalfampridine prior authorization program: a cohort study.
Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
[TBL] [Abstract][Full Text] [Related]
16. Novel Type 2 Diabetes Medication Access and Effect of Patient Cost Sharing.
Henk HJ; Lopez JMS; Bookhart BK
J Manag Care Spec Pharm; 2018 Sep; 24(9):847-855. PubMed ID: 30156451
[TBL] [Abstract][Full Text] [Related]
17. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Sinha A; Rajan M; Hoerger T; Pogach L
Diabetes Care; 2010 Apr; 33(4):695-700. PubMed ID: 20056950
[TBL] [Abstract][Full Text] [Related]
18. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
19. Benefit restrictions and gout treatment.
Wang SM; Aranda GA; Gao S; Patel BV
J Manag Care Pharm; 2013; 19(9):773-82. PubMed ID: 24156646
[TBL] [Abstract][Full Text] [Related]
20. Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not.
Chang HY; Kan HJ; Shermock KM; Alexander GC; Weiner JP; Kharrazi H
J Manag Care Spec Pharm; 2020 Oct; 26(10):1282-1290. PubMed ID: 32996394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
